Publication Date:
2016-06-30
Description:
Key Points Treatment of MF CD34+ cells with a TPO receptor antagonist selectively depletes MF HSCs and HPCs. Agents that target the TPO receptor represent potentially new approaches for the treatment of MF patients.
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink